Onyia Jude 4
4 · NEUROCRINE BIOSCIENCES INC · Filed Feb 3, 2026
Research Summary
AI-generated summary of this filing
Neurocrine (NBIX) CSO Onyia Jude Exercises RSUs; Shares Withheld
What Happened
Onyia Jude, Chief Scientific Officer of Neurocrine Biosciences (NBIX), had 238 restricted stock units (RSUs convertibles to common shares) vest and convert into shares on January 31, 2026. Of those, 142 shares were withheld by the company to satisfy tax withholding obligations at a per-share value reported as $136.06, totaling $19,321. The conversion shows an exercise/conversion price of $0.00 (typical for RSU vesting). After withholding, Jude received a net 96 shares (238 vested − 142 withheld), worth roughly $13,062 at $136.06/share.
Key Details
- Transaction date: 2026-01-31; Form filed: 2026-02-03.
- Conversion: 238 RSUs converted to common shares (reported as derivative exercise/ conversion).
- Tax withholding: 142 shares withheld @ $136.06/share = $19,321 (no shares sold on the open market).
- Net change to holdings from this vesting: +96 shares (approx. $13,062 at $136.06).
- Footnotes: F1 – shares withheld by the company to satisfy tax withholding; F2 – each RSU equals one share; F3 – RSU grant dated 2022-01-31 with prior tranches vesting in 2023–2025 and this final tranche vesting 2026-01-31.
- Filing timeliness: filing date is Feb 3, 2026; the form covers the Jan 31, 2026 vesting (filing timeliness not flagged in the report).
Context
This is a routine RSU vesting event and a tax-withholding action by the employer, not an open-market sale or purchase. Such withholdings are common and do not necessarily signal an insider’s view on the stock. For investors, outright purchases by insiders typically carry more weight as potential bullish signals; routine vesting and withholding are standard compensation mechanics.
Insider Transaction Report
- Exercise/Conversion
Common Stock
2026-01-31+238→ 16,119 total - Tax Payment
Common Stock
[F1]2026-01-31$136.06/sh−142$19,321→ 15,977 total - Exercise/Conversion
Restricted Stock Unit
[F2][F3]2026-01-31−238→ 0 total→ Common Stock (238 underlying)
Footnotes (3)
- [F1]Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold.
- [F2]Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
- [F3]This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 237 shares on January 31, 2023, vested as to 237 shares on January 31, 2024, vested as to 238 shares on January 31, 2025, and vested as to 238 shares on January 31, 2026, subject to the terms and conditions of the award.